Our Management

Martin Rosendale, Chief Executive Officer

Mr. Rosendale joined Cytomedix, Inc. in March 2008 as COO and he was appointed Chief Executive Officer in July 2008. Prior to joining Cytomedix, Mr. Rosendale was Chief Executive Officer of Core Dynamics, Inc. where he managed their Israel based R&D program and initiated U.S. commercial operations for cryobiology and cell lyophilization technologies. Mr. Rosendale has more than 24 years of specialty medical experience. He has held leadership positions for the past 15 years with American Red Cross, SangStat, North American Vaccine and ZLB Bioplasma, in addition to serving on the boards of the Transplant Recipients International Organization and the American Red Cross Biomedical Services, San Jose Region. Mr. Rosendale earned a Bachelor of Science degree in Microbiology from California State University.

 

Dean Tozer, Chief Commercial Officer

Mr. Tozer joined Cytomedix in April 2014. Prior to joining Cytomedix, he was Senior Vice President at Advanced BioHealing Inc. where he was responsible for the acquisition and reintroduction of Dermagraft® into the U.S. market. Following the acquisition of Advanced BioHealing by Shire Regenerative Medicine, Mr. Tozer became Vice President of Corporate Development where he led the business development efforts for that division including the 2012 acquisition of Pervasis Therapeutics. Mr. Tozer has more than 25 years of experience in the global healthcare industry and has an established track record of successfully launching and marketing wound care products. He also has eight years of global healthcare experience with Searle Pharmaceuticals, a Monsanto company. Mr. Tozer was also a founding executive and officer of the Alliance for Regenerative Medicine, where he served as Treasurer. He earned a Bachelor of Commerce degree from St. Mary’s University in Halifax, Canada and is a Certified Management Accountant.

 

Edward L. Field, Chief Operating Officer

Mr. Field has been employed at Cytomedix since February 2012. Aldagen since November 2004. Prior to joining Aldagen, Mr. Field was the President and Chief Executive Officer of Inologic, Inc., a private biopharmaceutical company, from 2002 to September 2004. Prior to joining Inologic, from 1999 to 2002, Ed was the President of Molecumetics, Ltd., a drug discovery and development subsidiary of Tredegar Corporation, until its merger with Therics, LLC, a regenerative medicine company.  Ed received a Master of Business Administration degree from the University of Virginia's Darden School of Business Administration and a Bachelor of Science degree in Economics from Duke University.

 

Steven A. Shallcross, CPA, Executive Vice President, Chief Financial Officer, Secretary and Treasurer

Mr. Shallcross joined Cytomedix, Inc. in May 2013. Mr. Shallcross has over 25 years of international financial, business and strategic planning experience, primarily working with companies in the pharmaceutical and biotechnology industries. Prior to Cytomedix, Mr. Shallcross served as Executive Vice President and Chief Financial Officer of Empire Petroleum Partners, LLC, a motor fuel distributor. Previously, he served as Acting Chief Financial Officer for Sensors for Medicine and Science, Inc., a medical device company. Prior to that, he was Executive Vice President and Chief Financial Officer of Innocoll Holdings, Inc., a biopharmaceutical company specializing in the development and commercialization of collagen based products. Mr. Shallcross is a certified public accountant. He received a Bachelor’s degree in Accounting from the University of Illinois and an M.B.A. degree from the University of Chicago, Booth School of Business.

 

Peter A. Clausen, Ph.D., Chief Science Officer

Dr. Clausen joined Cytomedix in September 2008 and has more than 20 years of experience in the biotechnology industry.   Prior to joining Cytomedix, Dr. Clausen was a founding member and Vice President of Research and Development at Marligen Bioscience, where he developed and commercialized innovative genomic and protein analysis products for the life sciences market.  Dr. Clausen was the Manager of New Purification Technologies at Life Technologies and the Invitrogen Corporation.   He also has significant experience within the commercial biotechnology industry developing peptide and small molecule therapeutics for application in the areas of inflammatory mediated disease and stem cell transplantation.  He completed his post-doctoral training at the Laboratory of Molecular Oncology at the National Cancer Institute where his research efforts focused in the areas of oncology, hematopoiesis, and gene therapy.  Dr. Clausen earned PhD in Biochemistry from Rush University in Chicago and a Bachelor of Science degree in Biochemistry from Beloit College.

 

Carelyn P. Fylling, R.N., M.S.N., C.W.S, C.L.N.C., Vice President, Professional Services

Ms. Fylling joined Cytomedix, Inc. in December 2001. Prior to Cytomedix,Ms. Fylling was recruited to start Curative Health Services, a biotechnology company specializing in the production of autologous platelet releasates for the management of chronic wounds. Since 1986, Ms. Fylling has been instrumental in developing point-of-care PRP systems, conducting clinical/outcome studies in chronic wounds, publishing and presenting on PRP, designing a national wound database, and training physicians and nurses in comprehensive wound management. She currently serves on the Board of Directors of the Association for the Advancement of Wound Care. She received her Bachelor of Science Degreein Nursing from North Park College, Chicago, IL and her Master of Science in Nursing from the University of California, San Francisco, Ca. 

  

David Jorden, Executive Board Director & Investor Relations

Mr. Jorden joined Cytomedix, Inc. in September 2008. He brings to Cytomedix more than 20 years of public and private company investment experience. Prior to joining Cytomedix, Mr. Jorden was responsible for equity portfolio management at Morgan Stanley's Private Wealth Management group and previously served as CFO at Genometrix, Inc., a private genomics/life sciences company. Mr. Jorden serves on the Board of Opexa Therapeutics, Inc., PLx Pharma, Inc., and DLush, a San Diego based deluxe beverage company. Mr. Jorden earned a Master of Management from the Kellogg School of Management at Northwestern University and a BBA from the University of Texas at Austin. He holds both CFA and CPA designations.

 

Andrew Cohen, Vice President, Marketing

Mr. Cohen joined Cytomedix in April 2014. He has more than 15 years of U.S. and international marketing experience in the life sciences industry, including 6 years in the wound care sector. He held several senior commercial positions at Advanced BioHealing Inc., including Director of Marketing, Director of International Marketing and Product Manager. His work there focused primarily on launching and building market share for Dermagraft®.  He developed a five-year strategic product plan, including new indication launch planning, brand and message evolution, new channel entry, and new technology market evaluation.  He was instrumental in creating the patient education program, Heal2gether. Most recently, Mr. Cohen was Vice President of Marketing at Millennium Laboratories, where he established and led cross-functional product management teams in their Medication Monitoring and Genetic Testing franchises through sales and customer support.  Earlier in his career, he held positions with Bio-Rad Laboratories, Sequana Therapeutics, and the NASA Ames Research Center.  Mr. Cohen earned a Bachelor of Science in Chemical Engineering from the University of California, Los Angeles, and holds a Masters Degree in Pacific and International Affairs from the University of California, San Diego.

 

Patrick P. Vanek, R.Ph., Vice President, Operations

Patrick Vanek joined Cytomedix, Inc. in July 2010. He brings to Cytomedix more than 30 years of diverse technical and managerial experience in pharmaceuticals and medical devices, specifically Formulation Design, Process Development, QA/QC and Supply Chain/Logistics. Prior to joining Cytomedix, Mr. Vanek spent 12 years at Otsuka America Pharmaceutical, Inc. where he rose through a number of managerial positions to become Vice President of Technical Operations. Prior to that, he held various development/technical management positions at KV Pharmaceutical Corp., Teva Pharmaceuticals USA, Wyeth Laboratories and McNeil Pharmaceutical. Mr. Vanek earned a B.S. in Pharmacy from the Philadelphia College of Pharmacy & Science and is a Registered Pharmacist.